Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
The products discussed online are manufactured peptides based on a researched sequence
Unlike other peptides like TB-500, BPC-157 has a unique origin and mechanism of action that targets connective tissue repair directly
You cant overdose, and theres no toxicity threshold
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Margie Bissinger 10:39 Also, certain medications
US$ 27.37
US$ 22.65
US$ 29.57
US$ 28.00
US$ 25.10
US$ 26.90
US$ 27.44